4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
7.99
-0.42 (-4.99%)
Nov 21, 2024, 4:00 PM EST - Market closed
4D Molecular Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Cash & Equivalents | 187.54 | 249.11 | 52.35 | 153 | 276.73 | 49.65 | Upgrade
|
| Short-Term Investments | 314.35 | 39.12 | 161.2 | 94.78 | - | - | Upgrade
|
| Cash & Short-Term Investments | 501.89 | 288.23 | 213.55 | 247.78 | 276.73 | 49.65 | Upgrade
|
| Cash Growth | 57.01% | 34.97% | -13.81% | -10.46% | 457.33% | -45.89% | Upgrade
|
| Accounts Receivable | - | - | - | 0.05 | 1.49 | 0.98 | Upgrade
|
| Other Receivables | - | - | - | 0.7 | - | - | Upgrade
|
| Receivables | - | - | - | 0.75 | 1.49 | 0.98 | Upgrade
|
| Prepaid Expenses | 8.87 | 8.36 | 6.96 | 7.76 | 4.44 | 1.88 | Upgrade
|
| Total Current Assets | 510.76 | 296.59 | 220.51 | 256.28 | 282.66 | 52.51 | Upgrade
|
| Property, Plant & Equipment | 41.63 | 31.67 | 35.35 | 28.95 | 5.07 | 5.05 | Upgrade
|
| Long-Term Investments | 48.78 | 10.95 | 4.91 | 67.65 | - | - | Upgrade
|
| Other Long-Term Assets | 2.86 | 0.68 | 1.08 | 0.6 | 0.6 | 0.68 | Upgrade
|
| Total Assets | 604.03 | 339.89 | 261.85 | 353.49 | 288.33 | 58.23 | Upgrade
|
| Accounts Payable | 2.92 | 3.52 | 3.32 | 4.76 | 1.79 | 1.74 | Upgrade
|
| Accrued Expenses | 21.42 | 12.01 | 8.87 | 7.74 | 8.37 | 5.35 | Upgrade
|
| Current Portion of Leases | 5.09 | 3.15 | 2.66 | 1.23 | - | - | Upgrade
|
| Current Unearned Revenue | 0.04 | 0.27 | 0.88 | 2.6 | 6.59 | 5.86 | Upgrade
|
| Total Current Liabilities | 29.47 | 18.95 | 15.73 | 16.34 | 16.74 | 12.96 | Upgrade
|
| Long-Term Leases | 19.74 | 11.52 | 13.47 | 15.22 | - | - | Upgrade
|
| Long-Term Unearned Revenue | 1.28 | 0.97 | 1.08 | 2.49 | 13.23 | 13.6 | Upgrade
|
| Other Long-Term Liabilities | 0.59 | 0.62 | 0.23 | 0.33 | 1.97 | 1.67 | Upgrade
|
| Total Liabilities | 51.08 | 32.06 | 30.51 | 34.38 | 31.94 | 28.22 | Upgrade
|
| Common Stock | 0.01 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Additional Paid-In Capital | 1,078 | 723.14 | 547.02 | 526.52 | 392.06 | 6.05 | Upgrade
|
| Retained Earnings | -526.52 | -415.33 | -314.49 | -207 | -135.68 | -79.03 | Upgrade
|
| Comprehensive Income & Other | 1.08 | 0.02 | -1.2 | -0.42 | - | - | Upgrade
|
| Total Common Equity | 552.95 | 307.83 | 231.34 | 319.11 | 256.39 | -72.97 | Upgrade
|
| Shareholders' Equity | 552.95 | 307.83 | 231.34 | 319.11 | 256.39 | 30.01 | Upgrade
|
| Total Liabilities & Equity | 604.03 | 339.89 | 261.85 | 353.49 | 288.33 | 58.23 | Upgrade
|
| Total Debt | 24.83 | 14.67 | 16.12 | 16.45 | - | - | Upgrade
|
| Net Cash (Debt) | 525.84 | 284.52 | 202.34 | 298.98 | 276.73 | 49.65 | Upgrade
|
| Net Cash Growth | 72.68% | 40.61% | -32.32% | 8.04% | 457.33% | -45.89% | Upgrade
|
| Net Cash Per Share | 10.36 | 7.27 | 6.25 | 10.78 | 43.03 | 9.66 | Upgrade
|
| Filing Date Shares Outstanding | 46.23 | 49.78 | 33.23 | 32.24 | 26.69 | 5.18 | Upgrade
|
| Total Common Shares Outstanding | 52 | 43.08 | 32.63 | 32.22 | 26.68 | 5.18 | Upgrade
|
| Working Capital | 481.29 | 277.64 | 204.78 | 239.94 | 265.91 | 39.55 | Upgrade
|
| Book Value Per Share | 10.63 | 7.15 | 7.09 | 9.90 | 9.61 | -14.09 | Upgrade
|
| Tangible Book Value | 552.95 | 307.83 | 231.34 | 319.11 | 256.39 | -72.97 | Upgrade
|
| Tangible Book Value Per Share | 10.63 | 7.15 | 7.09 | 9.90 | 9.61 | -14.09 | Upgrade
|
| Machinery | 16.01 | 14.61 | 12.61 | 7.12 | 5.85 | 4.71 | Upgrade
|
| Construction In Progress | 2.02 | 0.55 | 0.48 | 10.07 | 0.54 | 0.56 | Upgrade
|
| Leasehold Improvements | 17.33 | 16.9 | 16.9 | 2.53 | 2.53 | 2.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.